Live Breaking News & Updates on அகட சிகிச்சை இன்க்

Stay updated with breaking news from அகட சிகிச்சை இன்க். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Acorda: Q4 Earnings Snapshot


Acorda: Q4 Earnings Snapshot
FacebookTwitterEmail
ARDSLEY, N.Y. (AP) Acorda Therapeutics Inc. (ACOR) on Thursday reported fourth-quarter profit of $83 million.
On a per-share basis, the Ardsley, New York-based company said it had net income of $9.82. Losses, adjusted for non-recurring gains, came to $2.50 per share.
The drugmaker posted revenue of $38.2 million in the period.
For the year, the company reported that its loss narrowed to $99.6 million, or $12.32 per share. Revenue was reported as $153 million.
Acorda shares have climbed 64% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $6.78, a drop of 10% in the last 12 months. ....

Zacks Investment Research , Acorda Therapeutics Inc , Acorda Therapeutics , New York Based , Automated Insights , Zacks Investment , United States , North America White Plains , New York , Mc Complete State National , F Wire , Q4 Earnings Snapshot , ஜாக்கக்ஸ் முதலீடு ஆராய்ச்சி , அகட சிகிச்சை இன்க் , அகட சிகிச்சை , புதியது யார்க் அடிப்படையிலானது , தானியங்கி நுண்ணறிவு , ஜாக்கக்ஸ் முதலீடு , ஒன்றுபட்டது மாநிலங்களில் , வடக்கு அமெரிக்கா வெள்ளை சமவெளி , புதியது யார்க் , ம்ஸீ முழுமை நிலை தேசிய , எஃப் கம்பி ,

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), (ABUS) - The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings


Axsome Therapeutics Inc (NASDAQ: AXSM) (before the market open)
Amicus Therapeutics, Inc. (NASDAQ: FOLD) (before the market open)
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) (before the market open)
Athenex Inc (NASDAQ: ATNX) (before the market open)
Agile Therapeutics Inc (NASDAQ: AGRX) (after the close)
Atara Biotherapeutics Inc (NASDAQ: ATRA) (after the close)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) (after the close)
Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close)
Omeros Corporation (NASDAQ: OMER) (after the close)
ChemoCentryx Inc (NASDAQ: CCXI) (after the close)
FibroGen Inc (NASDAQ: FGEN) (after the close)
Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the close)
Precigen Inc (NASDAQ: PGEN) (after the close) ....

United States , Strongbridge Biopharma , Atara Biotherapeutics Inc , Terns Pharmaceuticals Inc , Biosystems Inc , Landos Biopharma Inc , Inovio Pharmaceuticals Inc , Opiant Pharmaceuticals Inc , Amicus Therapeutics Inc , Angion Biomedica Corp , Athenex Inc , Merck Co Inc , Pfizer Inc , Bolt Biotherapeutics Inc , Synthetic Biologics Inc , Orasure Technologies Inc , Fibrogen Inc , Axsome Therapeutics Inc , Clearpoint Neuro Inc , Passage Bio Inc , Lucira Health Inc , Aquestive Therapeutics Inc , Optinose Inc , Omeros Corporation , Therapeuticsmd Inc , Regenxbio Inc ,

Acorda Therapeutics Announces Completion of Sale of Manufacturing Operations to Catalent


Posted on
321
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has completed the sale of its manufacturing operations in Chelsea, Massachusetts to Catalent. Under the terms of the agreement, Catalent has paid Acorda $80 million in cash, resulting in expected net proceeds to Acorda of approximately $74 million after transaction fees and expenses and settlement of customary post-closing adjustments. In connection with the sale, Acorda and Catalent have entered into a long-term global supply agreement under which Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda’s patients and continued adherence to best-in-class manufacturing quality and safety standards. ....

Tierney Saccavino , Exchange Commission , Acorda Therapeutics Inc , Acorda Therapeutics , Extended Release Tablets , பரிமாற்றம் தரகு , அகட சிகிச்சை இன்க் , அகட சிகிச்சை , நீட்டிக்கப்பட்டது வெளியீடு மாத்திரைகள் ,